REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.00
-0.26 (-3.58%)
Oct 14, 2026, 10:11 AM EDT - Market open
REGENXBIO Revenue
REGENXBIO had revenue of $108.02M in the quarter ending June 30, 2026, with 405.73% growth. This brings the company's revenue in the last twelve months to $174.48M, up 12.00% year-over-year. In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth. That makes REGENXBIO the 18,437th largest company in the world by revenue and 2,970th in the United States.
Revenue (ttm)
$174.48M
Revenue Growth
+12.00%
P/S Ratio
2.65
Revenue / Employee
$470,302
Employees
371
Market Cap
462.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 163.30M |
| Aclaris Therapeutics | 8.22M |
| DBV Technologies | 5.04M |
| Allogene Therapeutics | 4.64M |
| Oculis Holding AG | 1.45M |
| ProKidney | 818.00K |
| Altimmune | 31.00K |
RGNX News
- 2 days ago - REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 - PRNewsWire
- 9 days ago - Regenxbio initiated with an Outperform at Mizuho - TheFly
- 19 days ago - Regenxbio presents positive 3-year durability data for Surabgene Lomparvove - TheFly
- 19 days ago - REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting - PRNewsWire
- 4 weeks ago - REGENXBIO Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - REGENXBIO Transcript: 2026 Global Healthcare Conference - Transcripts
- 5 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) - Business Wire